ProCE Banner Activity

Interactive Decision Support Tool: Expert Treatment Guidance for Metastatic Breast Cancer

Tool

Get recommendations from 5 experts on metastatic breast cancer for your specific patient case using this Interactive Decision Support Tool.

Released: November 21, 2023

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Erica L. Mayer

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Program Director Disclosure

Program Director

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP: consultant/advisor/speaker: AbbVie, AstraZeneca, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/stemline, Novartis, Pfizer, Scorpion Therapeutics, Seattle Genetics, Sun Pharma Advanced Research Company Ltd, Taiho Oncology; researcher (paid to institution): ADC Therapeutics, AstraZeneca, Blueprint Medicine, Debio Pharmaceuticals, Genentech, Gilead, Lilly, Merck, Novartis, Novita Pharmaceuticals, Pfizer, PUMA Biotechnology, Scorpion Therapeutics, Zymeworks.

Faculty Disclosure

Primary Author

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Erika P. Hamilton, MD: researcher (paid to institution): AbbVie, Acerra Pharma, Accutar Biotechnology, ADC Therapeutics, Akeso Bio Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, Atlas Medx, BeiGene, Black Diamond, Bliss Biopharmaceutical, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Stemcentrx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics , Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks; consultant/advisor (paid to institution): AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Gilead Sciences, Greenwich Life Sciences, Janssen, Jazz Pharmaceuticals, Lilly, Loxo, Medical Pharma Services, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Roche/Genentech, Seagen, Stemline Therapeutics, Thera Technologies, Tubulis, Veracity, Zentalis Pharmaceuticals. 

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: 4D Pharma, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini Silicon Biosystems, Mersna, Myovant Sciences, Oncosec, Puma Biotechnology, Seattle Genetics, Takeda; researcher: Ascentage, AstraZeneca, Genetech/Roche, Lilly, Novartis, SeaGen. 

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH: consultant/advisor/speaker: AstraZeneca, Gilead, Lilly, Novartis.

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Pharma, Lilly, G1 Therapeutics, Novartis, Puma; researcher (paid to institution): Genentech, Gilead, Lilly, Merck.